We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Femasys Inc (FEMY) USD0.001

Sell:$6.82 Buy:$7.44 Change: $0.18 (2.51%)
Market closed |  Prices as at close on 15 October 2021 | Switch to live prices |
Change: $0.18 (2.51%)
Market closed |  Prices as at close on 15 October 2021 | Switch to live prices |
Change: $0.18 (2.51%)
Market closed |  Prices as at close on 15 October 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Femasys Inc. is a biomedical company focused on transforming women’s healthcare. The Company is focused on providing women worldwide with non-surgical product technologies, accessible in the office, improving patient care and overall health economics. The Company has two lead product candidates: FemBloc and FemaSeed. FemBloc is a permanent birth control solution in development. FemaSeed is an artificial insemination infertility treatment. The Company also offers FemVue Saline-Air device for diagnosis of infertility and FemCerv Endocervical Sampler for diagnosis of cervical cancer. FemCerv is a sterile, single-use disposable endocervical curettage product that can be used to sample cervical cells and tissue, including in support of further testing following an abnormal Pap test to assess for any problems such as cancer, in a relatively pain-free office procedure.

Contact details

3950 Johns Creek Ct Ste 100
United States
+1 (770) 5003910

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$85.55 million
Shares in issue:
11.80 million
Health Care Equipment
United States
US dollar

Key personnel

  • Kathy Lee-Sepsick
    Chairman of the Board, President, Chief Executive Officer
  • Daniel Currie
    Senior Vice President - Operations
  • Gary Thompson
    Vice President of Finance and Administration
  • Steven Damon
    Vice President - Business & Commercial Development
  • Lexy Kelley
    Vice President, Finance & Administration
  • Mimi Zieman
    Vice President - Clinical Affairs

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.